RECOVERY Trial

Last updated

Recovery-logo-chosen-mar-2020.jpg

The Randomised Evaluation of COVID-19 Therapy (RECOVERY Trial) [1] is a large-enrollment clinical trial of possible treatments for people in the United Kingdom admitted to hospital with severe COVID-19 infection. [2] [3] [4] The trial was later expanded to Indonesia, Nepal and Vietnam. [5] The trial has tested ten interventions on adults: eight repurposed drugs, one newly developed drug and convalescent plasma. [2]

Contents

Overview

The RECOVERY Trial is a large-scale, randomized controlled trial. [2] [6] It is an "open label" study: people receiving the treatment and the attending clinicians both know which treatment is being administered. [2] It is a multi-arm adaptive clinical trial, meaning that new treatments can be added into the trial as it progresses, and other treatment "arms" closed to new enrolment when results have been produced. [4]

The very fast setting up of the trial was crucial for the fast-developing COVID-19 pandemic. Martin Landray, one of the trial's creators, said in March 2021 "I think it has set a new standard for what can be delivered and not just for pandemics. It would be a travesty if we went back to a situation where it takes years sometimes to get a trial off the ground." [7]

Enrollment

When people who have been hospitalised with COVID-19 are enrolled in the trial, they are automatically randomized to receive trial treatments. If any treatment is contra-indicated (or positively indicated) for that patient, or is not available, then that treatment is not included in the randomization process. The main randomization stage has three parts, so that patients might be allocated none, one, two or three of the trial treatments. If their disease progresses, there may also be a second randomization. [8]

Goals

The primary objective of the trial is to "provide reliable estimates of the effect of study treatments on all-cause mortality at 28 days after first randomization". [2] [6]

The trial protocol was developed in March 2020. The design minimizes the administrative load on hospital staff, who at the time were facing the prospect of overwhelming numbers of COVID-19 admissions. [9] [8]

Treatments

As of 25 June 2021, the following treatments are allocated at random to hospitalized people with severe COVID-19 infection: [2]

Children with PIMS-TS may also be allocated the following: [10]

The following treatments have previously been included in the trial and obtained positive results:

The following treatments have previously been included in the trial and were closed to new entrants after being shown to be ineffective. [11] [12] [13] [14] :

Operations

The trial is run by the Nuffield Departments of Population Health and of Medicine at the University of Oxford [12] [9] and supported by the National Institute for Health Research (NIHR). The study is led by Peter Horby and Martin Landray who serve as Co-Chief Investigators of the trial. [15] [16] By July 2020, the trial was in progress at 176 NHS hospitals in the UK, involving many thousands of health professionals. [17]

The trial began in March 2020. As of March 2021 the trial had enrolled more than 40,000 COVID-19 participants admitted to hospitals in the UK; [7] the estimated primary completion date was December 2021, and the estimated study completion date was December 2031. [6] [13]

Results

Dexamethasone

Mortality over 28 days for 1007 COVID-19 patients on mechanical ventilation at time of randomisation: 324 patients who received dexamethasone (red) compared to 683 who received standard hospital care (black) RECOVERY Trial Dexamethasone ventilated.jpg
Mortality over 28 days for 1007 COVID-19 patients on mechanical ventilation at time of randomisation: 324 patients who received dexamethasone (red) compared to 683 who received standard hospital care (black)

On 22 June 2020, preliminary results were published in a preprint showing that low-dose dexamethasone treatment reduced the death rate by one third in hospitalized people needing ventilators due to severe COVID-19 infection, and by one fifth in people treated with oxygen therapy. There was no benefit (and the possibility of harm) among people who did not require oxygen. [18] The preliminary report was subsequently published in The New England Journal of Medicine . [19]

Impacts

Six days before the pre-print, these results had been announced in a news release. [20] A UK Therapeutic Alert was issued the same day, and all the Chief Medical Officers in the United Kingdom exceptionally recommended an immediate change of UK-wide clinical practice, in advance of publication of any final paper. [21]

Demand for dexamethasone surged after publication of the preprint. [22]

Based on the preliminary, unpublished results of the RECOVERY trial, the US National Institutes of Health COVID-19 Treatment Guidelines Panel recommended dexamethasone in patients with COVID-19 who are on mechanical ventilation or those who require supplemental oxygen, and recommended against dexamethasone for those not requiring supplemental oxygen. [23]

Other countries granted specific approval for the drug as part of standard medical care, among them Japan, [24] Taiwan [25] and South Africa. [26]

A pre-print study, which was awarded Health Data Research UK Open Access Publication of the Month for August 2020, found that the discovery would save approximately 650,000 lives globally over the course of six months. [27] [28]

Limitations of dexamethasone result

Mortality over 28 days for 1535 COVID-19 patients not receiving oxygen at time of randomisation: 501 patients who received dexamethasone (red) compared to 1034 who received standard hospital care (black) RECOVERY Trial Dexamethasone Unassisted.jpg
Mortality over 28 days for 1535 COVID-19 patients not receiving oxygen at time of randomisation: 501 patients who received dexamethasone (red) compared to 1034 who received standard hospital care (black)
  • John Fletcher, research editor at the BMJ , noted that there were "limitations and causes of concern" in the dexamethasone results. [22]
  • Around a third of patients in the trial were still in hospital at the end of the 28-day trial period, so their final outcomes were not known. [22]
  • As an immunosuppressive drug, there are fears that dexamethasone could make the illness worse, and prolong the infection in patients where the immune system has not yet overreacted and caused inflammation. [9] [29]
  • The preprint authors themselves warned that "the results are consistent with possible harm" in patients who did not require oxygen at the time of enrolment. [18] The trial observed a 22% increase in mortality in these patients (rate ratio 1.22 [95% Confidence Interval 0.93 to 1.61]; p=0.14), though this observation may still be due to chance. [18]
  • Responding to the publication, the WHO emphasized that dexamethasone should only be used for patients with severe or critical disease, under close clinical supervision, stating that "There is no evidence this drug works for patients with mild disease or as a preventative measure, and it could cause harm." [30]

Confirmation of dexamethasone result

The results of this initial finding were replicated in a systematic review published in September 2020 by the WHO's Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. [31]

Hydroxychloroquine

On 5 June 2020, the trial determined that there was no clinical benefit from use of hydroxychloroquine in people hospitalized with COVID-19. [12]

Lopinavir-ritonavir

On 29 June 2020, chief investigators of the trial reported there was no clinical benefit from use of lopinavir-ritonavir in 1,596 people hospitalized with severe COVID-19 infection over 28 days of treatment. [11] These results were published in The Lancet on 5 October 2020. [32]

Azithromycin

In a news release on 14 December 2020, the chief investigators announced that they had found no benefit from azithromycin in patients hospitalised with COVID-19. 2582 patients had received azithromycin, and 5182 were randomised to usual care alone. 28-day mortality in both cohorts was 19%. [13] These preliminary results were released as a preprint on the same day. [33] [34]

Convalescent plasma

In a news release on 15 January 2021, the chief investigators announced the closure of the convalescent plasma arm of the trial. Among 1873 reported deaths from 10,405 patients, the trial reported "no significant difference in the primary endpoint of 28-day mortality (18% convalescent plasma vs. 18% usual care alone; risk ratio 1.04 [95% confidence interval 0.95-1.14]; p=0.34)". [14] The article with full results was published on 14 May 2021. [35]

Tocilizumab

Tocilizumab significantly reduces the risk of death when given to hospitalised patients with severe COVID-19. 2022 patients allocated to Tocilizumab were compared to 2094 who received standard hospital care. "596 (29%) of the patients in the tocilizumab group died within 28 days compared with 694 (33%) patients in the usual care group (rate ratio 0·86; [95% confidence interval [CI] 0·77 to 0·96]; p=0·007), an absolute difference of 4%." Receiving tocilizumab also increased the chance of discharge from hospital within 28 days. [36] [37] [38] [39]

This result supports the earlier findings of the Remap-Cap trial on the effectiveness of Tocilizumab for patients in intensive care, and extends those findings to a wider group of patients. [40]

See also

Related Research Articles

Dexamethasone Corticosteroid medication

Dexamethasone is a glucocorticoid medication used to treat rheumatic problems, a number of skin diseases, severe allergies, asthma, chronic obstructive lung disease, croup, brain swelling, eye pain following eye surgery, superior vena cava syndrome, and along with antibiotics in tuberculosis. In adrenocortical insufficiency, it may be used in combination with a mineralocorticoid medication such as fludrocortisone. In preterm labor, it may be used to improve outcomes in the baby. It may be given by mouth, as an injection into a muscle, as an injection into a vein, as a topical cream or ointment for the skin or as a topical ophthalmic solution to the eye. The effects of dexamethasone are frequently seen within a day and last for about three days.

Anakinra

Anakinra, sold under the brand name Kineret, is a biopharmaceutical medication used to treat rheumatoid arthritis, cryopyrin-associated periodic syndromes, familial Mediterranean fever, and Still's disease. It is a recombinant and slightly modified version of the human interleukin 1 receptor antagonist protein. It is marketed by Swedish Orphan Biovitrum. Anakinra is administered by subcutaneous injection.

Hydroxychloroquine Antimalarial medication

Hydroxychloroquine, sold under the brand name Plaquenil among others, is a medication used to prevent and treat malaria in areas where malaria remains sensitive to chloroquine. Other uses include treatment of rheumatoid arthritis, lupus, and porphyria cutanea tarda. It is taken by mouth, often in the form of hydroxychloroquine sulfate.

A cytokine storm, also called hypercytokinemia, is a physiological reaction in humans and other animals in which the innate immune system causes an uncontrolled and excessive release of pro-inflammatory signaling molecules called cytokines. Normally, cytokines are part of the body's immune response to infection, but their sudden release in large quantities can cause multisystem organ failure and death.

Tocilizumab, sold under the brand name Actemra among others, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis and systemic juvenile idiopathic arthritis, a severe form of arthritis in children. It is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer. Tocilizumab was jointly developed by Osaka University and Chugai, and was licensed in 2003 by Hoffmann-La Roche.

Lopinavir/ritonavir Combination medication for HIV/AIDS

Lopinavir/ritonavir (LPV/r), sold under the brand name Kaletra among others, is a fixed-dose combination antiretroviral medication for the treatment and prevention of HIV/AIDS. It combines lopinavir with a low dose of ritonavir. It is generally recommended for use with other antiretrovirals. It may be used for prevention after a needlestick injury or other potential exposure. It is taken by mouth as a tablet, capsule, or solution.

Olokizumab is an immunomodulator. It binds to interleukin 6. Hence acting as an Anti-IL-6 therapeutic aimed at inflammatory disease e.g. rheumatoid arthritis (RA).

Baricitinib

Baricitinib, sold under the brand name Olumiant among others, is a drug for the treatment of rheumatoid arthritis (RA) in adults whose disease was not well controlled by tumor necrosis factor (TNF) inhibitors. It acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2. The drug is approved for medical use in the European Union and in the United States. An important side effect of JAK inhibitors is serious bacterial, mycobacterial, fungal and viral infections.

Remdesivir Antiviral drug

Remdesivir, sold under the brand name Veklury, is a broad-spectrum antiviral medication developed by the biopharmaceutical company Gilead Sciences. It is administered via injection into a vein. During the COVID‑19 pandemic, remdesivir was approved or authorized for emergency use to treat COVID‑19 in numerous countries.

Oriol Mitjà Catalan researcher

Oriol Mitjà i Villar is a Catalan-born Spanish researcher and consultant physician in internal medicine and infectious diseases with expertise in poverty-related tropical diseases. He has conducted research at the Lihir Medical Centre in Papua New Guinea since 2010 on new diagnostic and therapeutic tools to eradicate yaws. He was awarded the Princess of Girona Award in the scientific research category. Currently at the Germans Trias i Pujol Research Institute, Mitjà is conducting research on SARS-CoV-2 coronavirus disease (COVID-19) and strategies to control the infection at a community level.

COVID-19 Contagious disease caused by SARS-CoV-2

Coronavirus disease 2019 (COVID-19) is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first known case was identified in Wuhan, China, in December 2019. The disease has since spread worldwide, leading to an ongoing pandemic.

COVID-19 drug repurposing research Drug repurposing research related to COVID-19

Drug repositioning is the repurposing of an approved drug for the treatment of a different disease or medical condition than that for which it was originally developed. This is one line of scientific research which is being pursued to develop safe and effective COVID‑19 treatments. Other research directions include the development of a COVID‑19 vaccine and convalescent plasma transfusion.

COVID-19 drug development Preventative and therapeutic medications for COVID-19 infection

COVID-19 drug development is the research process to develop preventative therapeutic prescription drugs that would alleviate the severity of coronavirus disease 2019 (COVID-19). From early 2020 through 2021, several hundred drug companies, biotechnology firms, university research groups, and health organizations were developing therapeutic candidates for COVID-19 disease in various stages of preclinical or clinical research, with 419 potential COVID-19 drugs in clinical trials, as of April 2021.

Solidarity trial Accelerated multinational clinical trial program to identify therapies against COVID-19

The Solidarity trial for treatments is a multinational Phase III-IV clinical trial organized by the World Health Organization (WHO) and partners to compare four untested treatments for hospitalized people with severe COVID-19 illness. The trial was announced 18 March 2020, and as of 6 August 2021, 12,000 patients in 30 countries had been recruited to participate in the trial.

Sir Peter William Horby is a British physician, epidemiologist, and Professor of Emerging Infectious Diseases and Global Health at the University of Oxford. He is the founder, and former director of the Oxford University Clinical Research Unit in Hanoi, Vietnam which was founded in 2006. In 2014, Horby established the Epidemic Research Group Oxford (ERGO). ERGO incorporates a number of international projects such as the European Commission funded PREPARE, the African coaLition for Epidemic Research, Response and Training (ALERRT), and the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). Since 2016, Horby has been chair and executive director of ISARIC.

There is no specific, effective treatment or cure for coronavirus disease 2019 (COVID‑19), the disease caused by the SARS-CoV-2 virus. One year into the pandemic, highly effective vaccines have now been introduced and are beginning to reduce mortality related to SARS-CoV-2; however, for those awaiting vaccination, as well as for the estimated millions of immunocompromised persons who are unlikely to respond robustly to vaccination, treatment remains important. Thus, the lack of progress developing effective treatments means that the cornerstone of management of COVID‑19 has been supportive care, which includes treatment to relieve symptoms, fluid therapy, oxygen support and prone positioning as needed, and medications or devices to support other affected vital organs.

Casirivimab/imdevimab Antiviral combination medication

Casirivimab/imdevimab, sold under the brand name REGEN-COV among others, is a combination medicine used for the treatment and prevention of COVID-19. It consists of two human monoclonal antibodies, casirivimab and imdevimab that must be mixed together and administered as an infusion or subcutaneous injection. The combination of two antibodies is intended to prevent mutational escape. It is also available as a co-formulated product. It was developed by the American biotechnology company Regeneron Pharmaceuticals.

Sir Martin Jonathan Landray is a British physician, epidemiologist and data scientist who serves as a Professor of Medicine & Epidemiology at the University of Oxford. Landray designs, conducts and analyses large-scale randomised control trials; including practice-changing international trials that have recruited over 100,000 individuals. Landray previously led the health informatics team that enabled the collection and management of data for the UK Biobank on over half a million people.

Bamlanivimab is a monoclonal antibody developed by AbCellera Biologics and Eli Lilly as a treatment for COVID-19. The medication was granted an emergency use authorization (EUA) by the US Food and Drug Administration (FDA) in November 2020, and the EUA was revoked in April 2021.

Chloroquine and hydroxychloroquine during the COVID-19 pandemic

Chloroquine and hydroxychloroquine are anti-malarial medications also used against some auto-immune diseases. Chloroquine, along with hydroxychloroquine, was an early experimental treatment for COVID-19. Neither drug prevents SARS-CoV-2 infection.

References

  1. "ISRCTN - ISRCTN50189673: A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus)". www.isrctn.com.
  2. 1 2 3 4 5 6 "RECOVERY Trial" . Retrieved 17 June 2020.
  3. "Coronavirus: Dexamethasone being used to treat NHS patients today". BBC News. 17 June 2020. Retrieved 17 June 2020.
  4. 1 2 "Biggest COVID-19 trial tests repurposed drugs first". Nature Biotechnology. 38 (5): 510. 11 May 2020. doi: 10.1038/s41587-020-0528-x . PMID   32393915. S2CID   218593584.
  5. "International sites — RECOVERY Trial". www.recoverytrial.net. Retrieved 17 May 2021.
  6. 1 2 3 Clinical trial number NCT04381936 for "Randomised Evaluation of COVID-19 Therapy (RECOVERY)" at ClinicalTrials.gov. 2 March 2021; page is updated from time to time.
  7. 1 2 Gallagher, James (25 March 2021). "Covid: The London bus trip that saved maybe a million lives". BBC News.
  8. 1 2 "Randomised evaluation of COVID-19 therapy (RECOVERY) – Trial protocol v11" (PDF). RECOVERY Trial. 21 November 2020. Retrieved 14 December 2020.
  9. 1 2 3 Fergus Walsh (20 June 2020). "At last some good news about coronavirus". BBC News. Retrieved 20 June 2020.
  10. "Recovery Trial Protocol v15" (PDF). Recovery Trial. Retrieved 4 February 2021.{{cite web}}: CS1 maint: url-status (link)
  11. 1 2 "No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in RECOVERY" (PDF). RECOVERY Trial: Statement from the Chief Investigators. 29 June 2020. Retrieved 30 June 2020.
  12. 1 2 3 "No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19". Recovery Trial, Nuffield Department of Population Health, University of Oxford, UK. 5 June 2020. Retrieved 7 June 2020.
  13. 1 2 3 Peter Horby; Martin Landray (14 December 2020). "RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19". RECOVERY Trial.
  14. 1 2 RECOVERY trial chief investigators (15 January 2021). "Recovery trial closes recruitment for convalescent plasma treatment for patients hospitalised with COVID-19" . Retrieved 15 January 2021.{{cite web}}: CS1 maint: url-status (link)
  15. "Preliminary trial results find dexamethasone reduces death in hospitalised patients with severe respiratory complications of COVID-19 - UK Research and Innovation". www.ukri.org. UK Research and Innovation. Retrieved 19 October 2020.
  16. editor, Sarah Boseley Health (17 June 2020). "Dexamethasone: low-cost drug helps prevent deaths of sickest coronavirus patients". The Guardian.{{cite news}}: |last1= has generic name (help)
  17. KupferschmidtJul. 2, Kai (2 July 2020). "One U.K. trial is transforming COVID-19 treatment. Why haven't others delivered more results?". Science. Retrieved 19 October 2020.
  18. 1 2 3 4 5 RECOVERY Collaborative Group (2020). "Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report". MedRXiv. doi: 10.1101/2020.06.22.20137273 . S2CID   219965377 . Retrieved 23 June 2020.
  19. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. (July 2020). "Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report". New England Journal of Medicine. 384 (8): 693–704. doi: 10.1056/NEJMoa2021436 . PMC   7383595 . PMID   32678530.
  20. "Dexamethasone reduces death in hospitalised patients with severe respiratory complications of COVID-19". University of Oxford. 16 June 2020. Retrieved 16 June 2020.
  21. "Dexamethasone in COVID-19" (PDF). 16 June 2020. Retrieved 23 June 2020.
  22. 1 2 3 Mahase E (June 2020). "Covid-19: Demand for dexamethasone surges as RECOVERY trial publishes preprint". BMJ. 369: m2512. doi: 10.1136/bmj.m2512 . PMID   32576548.
  23. "The National Institutes of Health COVID-19 Treatment Guidelines Panel Provides Recommendations for Dexamethasone in Patients with COVID-19". NIH COVID-19 Treatment Guidelines. National Institutes of Health. 25 June 2020. Retrieved 26 June 2020.
  24. hermesauto (22 July 2020). "Japan approves dexamethasone as coronavirus treatment". The Straits Times. Retrieved 6 September 2020.
  25. "Taiwan provisionally approves dexamethasone as coronavirus treatment". Reuters. 4 August 2020. Retrieved 6 September 2020.
  26. "South Africa approves dexamethasone to treat COVID-19".
  27. "The potential health and economic impact of dexamethasone treatment for patients with COVID-19". HDR UK. Retrieved 6 September 2020.
  28. Aguas, Ricardo; Mahdi, Adam; Shretta, Rima; Horby, Peter; Landray, Martin; White, Lisa J. (30 July 2020). "The potential health and economic impact of dexamethasone treatment for patients with COVID-19". medRxiv: 2020.07.29.20164269. doi:10.1101/2020.07.29.20164269. S2CID   220846974.
  29. Roni Caryn Rabin (24 June 2020). "Breakthrough Drug for Covid-19 May Be Risky for Mild Cases". New York Times. Retrieved 25 June 2020.
  30. "WHO Director-General's opening remarks at the media briefing on COVID-19 - 22 June 2020". World Health Organization. Retrieved 25 June 2020.
  31. The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group; Sterne, Jonathan A. C.; Murthy, Srinivas; Diaz, Janet V.; Slutsky, Arthur S.; Villar, Jesús; Angus, Derek C.; Annane, Djillali; Azevedo, Luciano Cesar Pontes; Berwanger, Otavio; Cavalcanti, Alexandre B. (2 September 2020). "Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis". JAMA. 324 (13): 1330–1341. doi:10.1001/jama.2020.17023. PMC   7489434 . PMID   32876694.
  32. Horby, Peter W.; Mafham, Marion; Bell, Jennifer L.; Linsell, Louise; Staplin, Natalie; Emberson, Jonathan; Palfreeman, Adrian; Raw, Jason; Elmahi, Einas; Prudon, Benjamin; Green, Christopher; Carley, Simon; Chadwick, David; Davies, Matthew; Wise, Matthew P.; Baillie, J Kenneth; Chappell, Lucy C.; Faust, Saul N.; Jaki, Thomas; Jefferey, Katie; Lim, Wei Shen; Montgomery, Alan; Rowan, Kathryn; Juszczak, Edmund; Haynes, Richard; Landray, Martin J. (5 October 2020). "Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial". The Lancet. 396 (10259): 1345–1352. doi:10.1016/S0140-6736(20)32013-4. PMC   7535623 . PMID   33031764.
  33. Horby, Peter W.; et al. (14 December 2020). "Azithromycin in Hospitalised Patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial". medRxiv. doi:10.1101/2020.12.10.20245944. S2CID   228634779 . Retrieved 14 December 2020.
  34. RECOVERY Collaborative Group (13 February 2021). "Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial". Lancet. 397 (10274): 605–612. doi:10.1016/S0140-6736(21)00149-5. hdl: 10044/1/86993 . PMC   7884931 . PMID   33545096.{{cite journal}}: CS1 maint: uses authors parameter (link)
  35. RECOVERY Collaborative Group (14 May 2021). "Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial". The Lancet. 397 (10289): 2049–2059. doi:10.1016/S0140-6736(21)00897-7. ISSN   0140-6736. PMC   8121538 . PMID   34000257.{{cite journal}}: CS1 maint: uses authors parameter (link)
  36. "Tocilizumab reduces deaths in patients hospitalised with COVID-19". Recovery Trial. 11 February 2021. Retrieved 11 February 2021.
  37. Michelle Roberts (11 February 2021). "Arthritis drug tocilizumab cuts deaths from Covid". BBC News Online. BBC. Retrieved 11 February 2021.
  38. Gupta S, Leaf DE (May 2021). "Tocilizumab in COVID-19: some clarity amid controversy". Lancet. 397 (10285): 1599–1601. doi: 10.1016/S0140-6736(21)00712-1 . PMC   8084409 . PMID   33933194.
  39. RECOVERY Collaborative Group (1 May 2021). "Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial". Lancet. 397 (10285): 1637–1645. doi:10.1016/S0140-6736(21)00676-0. hdl: 2164/16630 . PMC   8084355 . PMID   33933206.{{cite journal}}: CS1 maint: uses authors parameter (link)
  40. Nicola Davis (11 February 2021). "Arthritis drug that helps Covid ICU patients has wider benefits, trial finds". Guardian News. The Guardian. Retrieved 11 February 2021.